<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809025</url>
  </required_header>
  <id_info>
    <org_study_id>EBPS</org_study_id>
    <nct_id>NCT04809025</nct_id>
  </id_info>
  <brief_title>Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer</brief_title>
  <acronym>EBPS</acronym>
  <official_title>Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the hypothesis that the diagnosis for histological type, histological&#xD;
      grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status in gastric cancer is at&#xD;
      least as reliable when performed on endoscopic biopsy specimens as on surgical resection&#xD;
      specimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most institutions currently diagnose gastric cancer on endoscopic biopsy specimens but use&#xD;
      surgical resection specimens for histological type, histological grade, LAUREN type, HER-2&#xD;
      expression, MSI/dMMR status and EBV status testing. However, gastric cancers treated with&#xD;
      neoadjuvant chemoradiotherapy/chemotherapy may undergo a complete pathological response&#xD;
      (pCR), with no residual tumors available for testing, and neoadjuvant&#xD;
      chemoradiotherapy/chemotherapy may alter the HER-2 expression, MSI/dMMR status and EBV status&#xD;
      of the gastric cancer in some instances. Importantly, testing histological type, histological&#xD;
      grade, LAUREN type, HER-2 expression, MSI/dMMR status and EBV status of gastric cancer on&#xD;
      endoscopic biopsy material could be initiated preoperatively, allowing resultant genetic&#xD;
      information to be used in consultation with the patient to inform treatment decisions.&#xD;
      Therefore, the preoperative endoscopic biopsy may be a source of suitable and reliable&#xD;
      testing material. This study aims to investigate the correlation between histological type,&#xD;
      histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status in&#xD;
      preoperative endoscopic biopsy specimens and their corresponding surgical resection specimens&#xD;
      and ascertain whether endoscopic biopsy specimen is a valid and reliable testing material for&#xD;
      determining the histological type, histological grade, LAUREN type, HER-2 expression,&#xD;
      MSI/dMMR status and EBV status of gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>2-year</time_frame>
    <description>The primary outcome of this trial is to investigate the correlation between histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status and EBV status in pretreatment endoscopic biopsy specimens and their corresponding surgical resection specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of incomplete molecular pathology detection</measure>
    <time_frame>2-year</time_frame>
    <description>incomplete molecular pathology detection defined as endoscopic biopsy specimens and surgical resection specimens from which the definitive histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status and EBV status diagnosis cannot be rendered by the pathologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>2-year</time_frame>
    <description>The total length of time for the diagnosis of histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status and EBV status performed on endoscopic biopsy specimens and surgical resection specimens will be documented(days).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Endoscopy</condition>
  <condition>Biopsy</condition>
  <condition>Pathology</condition>
  <arm_group>
    <arm_group_label>the pathology of endoscopic biopsy</arm_group_label>
    <description>The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the pathology of surgical resection specimen</arm_group_label>
    <description>The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endoscopy</intervention_name>
    <description>gastroscope</description>
    <arm_group_label>the pathology of endoscopic biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>radical gastrectomy</description>
    <arm_group_label>the pathology of surgical resection specimen</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      preoperative endoscopic biopsy specimens and postoperative specimen of gastric tumors&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naive gastric cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.&#xD;
&#xD;
          2. Histologically proven primary gastric adenocarcinoma (Diagnostic biopsies must be&#xD;
             collected within 12 months prior to enrollment).&#xD;
&#xD;
          3. Written informed consent from the patient.&#xD;
&#xD;
          4. Patients planned for radical R0 gastrectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female in pregnancy or lactation.&#xD;
&#xD;
          2. Patients with gastric cancer who can not undergo tumor resection&#xD;
&#xD;
          3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney,&#xD;
             or liver disease, complicated by poorly controlled hypertension, diabetes, mental&#xD;
             disorders or diseases.&#xD;
&#xD;
          4. Patients with poor compliance or considered to be poor compliance.&#xD;
&#xD;
          5. Patients received any anticancer drugs, biotherapy, radiotherapy or immunotherapy&#xD;
             within 4 weeks before or after enrollment.&#xD;
&#xD;
          6. Patients after organ transplantation, long-term need to take immunosuppressants,&#xD;
             autoimmune diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dazhi Xu, PHD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dazhi Xu, PHD, MD</last_name>
    <phone>(+86) 021-38196215</phone>
    <email>xudzh@sysucc.org.cn</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Dazhi Xu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Biopsy</keyword>
  <keyword>Pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

